Fig. 2: The pleiotropic changes in response to single-agent and combined therapy suggested that TCC might activate the immune response to tumours. | Cell Death & Disease

Fig. 2: The pleiotropic changes in response to single-agent and combined therapy suggested that TCC might activate the immune response to tumours.

From: Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Fig. 2

a We collected resected tumours from mouse PDX models and conducted scRNA-seq. The tSNE plots of DEGs (b) and cell clusters (c). d Twenty main cell clusters were identified among cells from 6 groups with the expression of certain marker genes. e These identified cell clusters could be assigned to known cell lineages through 20 marker genes. f After observing changes in the number of cells in each cluster after treatment with a single agent or combined agent, different clusters showed pleiotropic changes. Differentially expressed genes among the 6 groups were used to carry out gene enrichment analysis (g) and pathway enrichment analysis (h).

Back to article page